These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27995531)

  • 41. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
    Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
    Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial.
    Patten SB; Metz LM
    Mult Scler; 2001 Aug; 7(4):243-8. PubMed ID: 11548984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Interferon-alpha2b recombinant improved the cognitive dysfunction in patients with relapsing remitting multiple sclerosis].
    Cabrera-Gómez JA; Echazábal-Santana N; Porrero-Martín P; Valenzuela-Silva C; Rodríguez CA; Fuentes-Suárez I; Pérez-Ruiz L; Ramos-Cedeño AM; Cabrera-Núñez JA;
    Rev Neurol; 2003 Aug 1-15; 37(3):214-20. PubMed ID: 12938052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
    Bayas A; Ouallet JC; Kallmann B; Hupperts R; Fulda U; Marhardt K;
    Expert Opin Drug Deliv; 2015 Aug; 12(8):1239-50. PubMed ID: 26098143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study.
    Wray S; Hayward B; Dangond F; Singer B
    Expert Opin Drug Deliv; 2018 Feb; 15(2):127-135. PubMed ID: 29206056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
    Limmroth V; Malessa R; Zettl UK; Koehler J; Japp G; Haller P; Elias W; Obhof W; Viehöver A; Meier U; Brosig A; Hasford J; Putzki N; Kalski G; Wernsdörfer C;
    J Neurol; 2007 Jan; 254(1):67-77. PubMed ID: 17273808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
    Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
    Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
    Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study.
    Ghezzi A; Bianchi A; Baroncini D; Bertolotto A; Malucchi S; Bresciamorra V; Lanzillo R; Milani N; Martinelli V; Patti F; Chisari C; Rottoli M; Simone M; Paolicelli D; Visconti A;
    Neurol Sci; 2017 Nov; 38(11):1999-2005. PubMed ID: 28831635
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.
    Liu Y; Vollmer T; Havrdova E; Riester K; Lee A; Phillips G; Wang P; Sabatella G
    Mult Scler Relat Disord; 2017 Jan; 11():18-24. PubMed ID: 28104250
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.
    Kappos L; Kuhle J; Multanen J; Kremenchutzky M; Verdun di Cantogno E; Cornelisse P; Lehr L; Casset-Semanaz F; Issard D; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1202-7. PubMed ID: 26374702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
    Leuschen MP; Filipi M; Healey K
    Mult Scler; 2004 Dec; 10(6):636-42. PubMed ID: 15584488
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.
    Barbero P; Verdun E; Bergui M; Pipieri A; Clerico M; Cucci A; Ricci A; Bergamasco B; Durelli L
    J Neurol Sci; 2004 Jul; 222(1-2):13-9. PubMed ID: 15240190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trial.
    Harand C; Daniel F; Mondou A; Chevanne D; Creveuil C; Defer G
    Trials; 2019 Oct; 20(1):614. PubMed ID: 31665039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS.
    Francis GS
    J Neurol; 2004 Sep; 251 Suppl 5():v42-v49. PubMed ID: 15549355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
    Patti F; Morra VB; Amato MP; Trojano M; Bastianello S; Tola MR; Cottone S; Plant A; Picconi O;
    PLoS One; 2013; 8(8):e74111. PubMed ID: 24137499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.